Nature's Sunshine Products Inc. (NATR) exhibits 72.4% gross margins and 28.9% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 4.0x enterprise multiple and 4.8% implied options volatility.
Sustained 72.4% gross profitability converts into 5.2% operating margin and 28.9% ROIC, outpacing sector cost of capital.
ROIC: 28.9% // GM: 72.4%YoY revenue trajectory of +5.7% paired with 13.35% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +5.7% // FCF YLD: 13.35%Altman Z-Score of 4.33 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 4.33 // F-SCORE: 8/9Trading at 11.1x trailing P/E (10.3x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 11.1x // EV/EBITDA: 4.0xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $12.25 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 4.1% net margins.
NET MARGIN: 4.1% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for NATR & activate live FRED threshold breach alerts.